Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bevacizumab by Outlook Therapeutics for Branch Retinal Vein Occlusion: Likelihood of Approval
Bevacizumab is under clinical development by Outlook Therapeutics and currently in Phase III for Branch Retinal Vein Occlusion. According to...
Bevacizumab by Outlook Therapeutics for Diabetic Macular Edema: Likelihood of Approval
Bevacizumab is under clinical development by Outlook Therapeutics and currently in Phase III for Diabetic Macular Edema. According to GlobalData,...
Bevacizumab by F. Hoffmann-La Roche for Colorectal Cancer: Likelihood of Approval
Bevacizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Colorectal Cancer. According to GlobalData,...
Bevacizumab by F. Hoffmann-La Roche for Malignant Mesothelioma: Likelihood of Approval
Bevacizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Malignant Mesothelioma. According to GlobalData,...
Bevacizumab by F. Hoffmann-La Roche for Small-Cell Lung Cancer: Likelihood of Approval
Bevacizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Small-Cell Lung Cancer. According to...
Bevacizumab by F. Hoffmann-La Roche for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Bevacizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...
Bevacizumab by F. Hoffmann-La Roche for Neuroblastoma: Likelihood of Approval
Bevacizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...
Bevacizumab by F. Hoffmann-La Roche for Endometrial Cancer: Likelihood of Approval
Bevacizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Endometrial Cancer. According to GlobalData,...